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Immunization is key to preventing infectious diseases, a leading cause of death early in 
life. However, due to age-specific immunity, vaccines often demonstrate reduced effi-
cacy in newborns and young infants as compared to adults. Here, we combined in vitro 
and in vivo approaches to identify adjuvant candidates for early life immunization. We 
employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a 
screening of pattern recognition receptor agonists and found that the stimulator of inter-
feron genes ligand 2′3′-cGAMP (hereafter cGAMP) induces a comparable expression of 
surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent 
recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to inves-
tigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone 
could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, 
as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum 
(Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody 
subclass associated with the development of IFNγ-driven type 1 immunity in vivo and 
endowed with higher effector functions, by 42 days of life. Highlighting the amenability 
for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs 
onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted 
IFNγ production by CD4+ T cells and increased the proportions and absolute numbers of 
CD4+ CXCR5+ PD-1+ T follicular helper and germinal center (GC) GL-7+ CD138+ B cells, 
suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently 
specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as 
there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP 
when formulated with alum may represent an effective adjuvantation system to foster 
humoral and cellular aspects of type 1 immunity for early life immunization.
Keywords: vaccines, adjuvants, newborn, antigen-presenting cells, germinal centers, T follicular helper cells, 
antibodies, stimulator of interferon genes
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inTrODUcTiOn
Infectious diseases represent a major cause of morbidity and 
mortality in neonates and young infants (1, 2). For example, 
each year in the US ~20,000 children <5 years old are hospital-
ized due to influenza complications and flu-related death may 
occur, especially among those with underlying chronic illness 
(3). Immunization strategies are fundamental to prevent infec-
tious diseases. However, due to age-specific immunity, vaccines 
often demonstrate reduced efficacy in newborns and young 
infants compared to adults (4, 5). Newborn innate immune 
cells exhibit distinct activation profiles in response to pattern 
recognition receptor (PRR) agonists (6, 7), and only certain PRR 
agonists (e.g., TLR7/8 agonists) (8–14) or their combinations 
(15, 16) are able to induce an adult-like response. The newborn 
adaptive immune compartment presents distinct features that 
may also limit vaccine efficacy. Neonatal B  cells can produce 
immunoregulatory cytokines (e.g., IL-10) (17–20), and the 
magnitude and persistence of the antibody response are reduced 
(21). Several mechanisms may contribute to distinct immunity 
in early life, including distinct activity of B and plasma cells 
(22, 23), the presence of maternal antibodies, impaired CD4+ 
CXCR5+ PD-1+ T follicular helper (Tfh) cell differentiation 
and lymph node germinal center (GC) reaction (24, 25) that 
may adequately support the antigen-specific B  cell response. 
Moreover, neonatal CD4+ T cells produce lower amounts of IFNγ 
and are skewed toward Th2, Th17, and Treg polarization (6, 7). Of 
note, adjuvants exhibit age-specific patterns of Th-polarization 
(16) such that adjuvantation systems that boost adult immune 
responses do not necessarily lead to enhanced vaccine efficacy in 
newborns or young infants (26). Therefore, identification of vac-
cine adjuvants capable of activating neonatal and infant immune 
responses may inform development of adjuvanted vaccine for-
mulations that enhance early life immunization (8, 9).
Dendritic cells (DCs) play a pivotal role in activating T cells 
and instructing the adaptive immune response. They express 
a high diversity of PRRs, whose activation leads to DC migra-
tion to lymph nodes and enhancement of immune-stimulatory 
functions (27). Recently, a systems vaccinology analysis of young 
infants vaccinated with trivalent inactivated influenza vaccine 
with or without the oil-in-water adjuvant MF59 demonstrated 
that innate immune gene signatures (e.g., antiviral and DC 
genes) 1 day post-immunization correlated with vaccine efficacy, 
highlighting the importance of robust innate immune activation 
in early life immunization (28). Agonists of the intracellular 
receptors TLR7/8, that recognize viral single-stranded RNAs, 
potently activate Th1-polarizing responses, including expression 
of interferons (IFNs), production of IL-12p70 and upregulation of 
co-stimulatory molecules in newborn DCs in vitro and enhance 
vaccine efficacy in newborn non-human primates in vivo (8–14). 
Moreover, adjuvantation with the TLR9 agonist CpG increases 
CG Tfh and B cell responses in newborn mice (25). Among intra-
cellular PRRs, the stimulator of interferon genes (STING) is an 
amenable target for adjuvant discovery and development (29, 30). 
It binds cyclic dinucleotides (CDNs) derived from bacteria (i.e., 
c-di-AMP, c-di-GMP, and 3′3′-cGAMP) or synthesized in mam-
malian cells by cGAMP synthase in response to double-stranded 
DNA in the cytoplasm (i.e., 2′3′-cGAMP). Upon activation, 
STING induces the TBK-1-mediated phosphorylation of IRF3, 
which in turn modulates the expression of type I IFNs, IFN-
stimulated genes, and also promotes DC maturation and type 1 
(i.e., IFNγ-driven) immunity (31). Accordingly, STING agonists 
have demonstrated promising adjuvanticity in adult experimen-
tal models of parenteral and mucosal immunization as well as 
cancer immunotherapy (32–49). However, to our knowledge, 
STING has not yet been investigated as an adjuvant target for 
early life immunization.
Here, we took an unbiased approach to identify PRR-based 
agonists for early life immunization. We employed adult and 
neonatal bone marrow-derived DCs (BMDCs) to screen the 
activity of a comprehensive panel of PRR agonists and adjuvants, 
and found that the STING ligand 2′3′-cGAMP is a potent activa-
tor of newborn BMDCs. Strikingly, we found that 2′3′-cGAMP 
formulated with alum induces antibody isotype switching toward 
IgG2a/c, a subclass endowed with higher effector functions, 
appears to enhance the GC reaction and also promotes Th1 
polarization in immunized newborn mice. Altogether, our study 
supports the use of STING ligands and their formulations for 
enhancement of early life immunization.
MaTerials anD MeThODs
ethics statements
All experiments involving animals were approved by the Animal 
Care and Use Committee of Boston Children’s Hospital and 
Harvard Medical School (protocol numbers 15-11-3011 and 
16-02-3130).
animals
C57BL/6 and BALB/c mice were obtained from Taconic 
Biosciences or Charles River Laboratories and housed in specific 
pathogen-free conditions in the animal research facilities at 
Boston Children’s Hospital. For breeding purposes, mice were 
housed in couples, and cages checked daily to assess pregnancy 
status of dams and/or the presence of pups. When a new litter was 
discovered, that day was recorded as day of life (DOL) 0. Both 
male and female pups were used for experiments.
generation of neonatal and adult Murine 
Bone Marrow-Derived Dendritic cells 
(BMDcs)
BMDCs were generated from newborn (5–7 days old) and adult 
(6–12 weeks old) C57BL/6 mice with an adaptation of previously 
described methods (50, 51). Briefly, mice were sacrificed and 
legs removed; bones were surgically cleaned from surrounding 
tissue, extremities of tibiae and femurs were trimmed with sterile 
scissors and bone marrow flushed through a 70-µm nylon mesh 
strainer (Corning Life Sciences). Cell number and viability was 
determined by trypan blue exclusion. Whole bone marrow cells 
were plated into non-tissue culture-treated 100 mm Petri dishes 
(Corning Life Sciences) at a density of 0.3 × 106 cells/ml in 10 ml 
total volume/plate of complete culture medium (RPMI 1640 plus 
10% heat-inactivated fetal bovine serum [FBS, GE Healthcare 
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HyClone], 50  µM 2-mercaptoethanol, 2  mM l-glutamine, 100   
U/ml penicillin/streptomycin [Gibco ThermoFisher Scientific]) 
supplemented with 20  ng/ml of recombinant murine GM-CSF 
(rmGM-CSF, R&D systems). Plates were incubated in humidified 
atmosphere at 37°C, 5% CO2 for 6 days, with one supplement of 
10 ml of complete culture medium and rmGM-CSF on day 3. On 
day 6, non-adherent and loosely adherent cells were harvested 
by washing the plate gently with culture medium. Adherent 
cells were discarded. For flow cytometry analysis, BMDCs were 
stained (20 min at 4°C) in PBS + FBS 2% + EDTA 2 mM, fixed 
with formaldehyde 4% [10 min at room temperature (RT)] and 
acquired on a BD LSRFortessa flow cytometer (BD Biosciences) 
or a Sony spectral analyzer SP6800 (Sony Biotechnology) and 
data were analyzed using FlowJo v.10 software (Tree Star). For a 
complete list of antibodies and fluorochromes used in the study, 
see Table S1 in Supplementary Material.
Prrs agonists, adjuvants, and BMDc 
In Vitro stimulation
Rough (Salmonella Minnesota, R595) and smooth (Escherichia 
coli, O55:B5) lipopolysaccharide (LPS) were purchased from 
List Biological Laboratories. Aluminum hydroxide (Alhydrogel) 
and Aluminum phosphate (Adju-phos) were purchased from 
Brenntag Biosector. All remaining PRR agonists and adjuvants, as 
indicated in Table S2 in Supplementary Material, were purchased 
from Invivogen. All PRR agonists employed in the studies were 
chosen based on and verified endotoxin free as indicated by the 
manufacturers. For stimulation experiments, immature BMDCs 
generated from newborn and adult mice were plated in round 
bottom 96-wells non-tissue culture-treated plates at the density 
of 105 cells/well in 200 µl of fresh complete culture medium with 
rmGM-CSF as described above, with the appropriate stimuli at the 
concentrations indicated in Table S2 in Supplementary Material. 
Cells were incubated at 37°C for 20–24 h, then supernatant har-
vested and TNF, IL-6, IL-1β, and IL-12p70 concentrations were 
measured by ELISA (R&D Systems). IFNβ was measured with a 
bioluminescent ELISA kit (LumiKine, Invivogen). Alternatively, 
BMDCs were stained and analyzed by flow cytometry as indi-
cated above. For experiments involving blocking antibodies, 
BMDCs were pre-incubated for 20 min at 37°C with anti-mouse 
IFNAR1 (clone MAR1-5A3, 10 µg/ml, Biolegend) or anti-mouse 
TNF (clone MP6-XT22, 10 µg/ml, Biolegend) antibodies or an 
isotype control before stimulation.
antigens, immunization, and antibody 
Quantification
Both neonate and adult mice were immunized intramuscularly 
(i.m.) in the right posterior thigh with 50 µl of the 2016–2017 
formulation of the FluBlok vaccine (Protein Sciences Corp.) con-
taining 0.33 µg of each of the following recombinant influenza 
virus hemagglutinins (rHA): A/Michigan/45/2015 (H1N1), A/
Hong Kong/4801/2014 (H3N2), and B/Brisbane/60/2008. Mice 
were immunized with a single dose at DOL 7 or a prime-boost 
schedule (two injections 1  week apart, for newborn mice at 
DOL 7 and 14). As indicated for specific experimental groups, 
the vaccine was formulated with Aluminum hydroxide (100 µg, 
hereafter “alum”) with or without 2′3′-cGAMP (10 µg). Serum 
was collected at the indicated intervals for antibody detection. 
rHA-specific IgG, IgG1, IgG2c (for C57BL/6 mice), and IgG2a 
(for BALB/c mice) antibodies were quantified by ELISA. High 
binding flat bottom 96-well plates (Corning Life Sciences) were 
coated with 1 µg/ml rHA in carbonate buffer pH 9.6, incubated 
overnight at 4°C and blocked with PBS  +  BSA 1% (Sigma-
Aldrich) for 1  h at RT. Then, sera from vaccinated mice were 
added with an initial dilution of 1:100 and 1:4 serial dilutions 
in PBS + BSA 1% and incubated for 2 h at RT. Plates were then 
washed and incubated for 1 h at RT with HRP-conjugated anti-
mouse IgG, IgG1, IgG2c, or IgG2a (Southern Biotech). At the 
end of the incubation, plates were washed again and developed 
with tetramethylbenzidine (BD Biosciences) for 5  min, then 
stopped with 2 N H2SO4. The optical density was read at 450 nm 
Versamax microplate reader with SoftMax Pro Version 5 (both 
from Molecular Devices) and endpoint titers were calculated 
using as cutoff three times the optical density of the background.
For assessing antibody avidity, plates were incubated 15 min 
with ammonium thiocyanate 0.5 M before the addition of HRP-
conjugated anti-mouse IgG antibodies. Avidity was expressed as 
the LogEC50 ratio of corresponding plates treated with or without 
ammonium thiocyanate.
Quantification of 2′3′-cgaMP adsorption 
onto alum
To quantify the extent of 2′3′-cGAMP adsorption to aluminum 
hydroxide (Alhydrogel) we mixed 100 µg/100 μl of 2′3′-cGAMP 
with 1000 µg/100 μl of alum (a 1:10 cGAMP:alum mass ratio) 
plus 300  µl of 0.9% saline. After vortexing for 10  s the sample 
was placed in a 37°C incubator. Every 15 min, the sample was 
vortexed for an additional 5 s and placed back into the incubator. 
Aliquots were taken at t = 0.25, 0.5, 1, 2, 4 and 24 h and centri-
fuged at 3,000 RPM (rcf = 664 g) to separate the alum from the 
supernatant. Supernatant was immediately removed and placed 
into an autosampler vial undiluted for analysis by reverse-phase 
high-performance liquid chromatography (RP-HPLC) to deter-
mine adsorption as a function of time. RP-HPLC samples were 
run on a Waters 2695 HPLC equipped with a 2996 photodiode 
array detector at a wavelength of 254 nm. A gradient was per-
formed using a two mobile phase system of 0.1% trifluoroacetic 
acid in water and 0.1% trifluoroacetic acid in acetonitrile, on an 
Agilent Zorbax Eclipse Plus C18, 4.6 × 150 mm, 5 µm column 
at 25°C. The response (peak area) of the samples were compared 
against a 50 µl 2′3′-cGAMP plus 200 µl 0.9% saline control and a 
separate 100 µl alum plus 400 µl saline control.
In Vitro restimulation of rha-specific  
T cell responses
Splenocytes from immunized mice were harvested 10  days 
post-boost (DOL 24) as previously reported (25, 52, 53) and re-
stimulated in vitro to assess cytokine production by flow cytom-
etry. Spleens were mashed through a 70 µM strainer, washed with 
PBS, and erythrocytes were lysed with 2  min of incubation in 
ammonium chloride-based lysis buffer (BD Biosciences). Cells 
were then counted and plated 2 ×  106 per well (round bottom 
4Borriello et al. Targeting STING for Neonatal Immunization
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1772
96-well plate) in 200  µl of complete culture medium with or 
without rHA 10  µg/ml or rHA 10  µg/ml +  anti-mouse CD28 
2 µg/ml (BioLegend). Plates were incubated for 18 h at 37°C with the 
addition of Brefeldin A (BD Biosciences) for the last 6 h. Cells were 
stained against for surface antigens in (PBS + BSA 0.2% + NaN3 
0.05%) for 20 min at 4°C, then fixed with formalin 2% (10 min at 
RT) and permeabilized with intracellular staining permeabiliza-
tion wash buffer (BioLegend) for 20 min at 4°C. Finally, cells were 
stained with conjugated antibodies against IFNγ, IL- 2, IL-4, and 
IL-17. Data were acquired on a BD LSRFortessa flow cytometer 
(BD Biosciences) and analyzed using FlowJo v.10 software (Tree 
Star). For a complete list of antibodies and fluorochromes used in 
the study, see Table S1 in Supplementary Material.
analysis of the gc reaction
Draining (inguinal) lymph nodes (dLNs) from immunized mice 
were harvested 10 days post-boost (DOL 24) as previously reported 
(25, 52, 53). To prepare a single-cell suspension, dLNs were pressed 
using the plunger end of a syringe. Then, cells were washed and 
stained with the following antibodies: for GC Tfh cells, anti-CD45, 
anti-B220, anti-CD3, anti-CD4, anti-programmed death-1 (CD279 
or PD-1), anti-CXCR5; for GC B cells, anti-CD45, anti-B220, anti-
CD3, anti-GL7, and anti-Syndecan-1 (CD138) (all from BioLegend). 
GC Tfh cells were defined as viable singlet CD45+ B220− CD3+ 
CD4+ CXCR5+ PD-1+ cells. GC B cells were defined as viable singlet 
CD45+ B220+ CD3− CD138− GL-7+. Cells were acquired on a BD 
LSRFortessa (BD Biosciences) and data were analyzed using FlowJo 
v.10 software (Tree Star). Absolute number of cell subsets were deter-
mined using CountBright Absolute Counting Beads (ThermoFisher 
Scientific). For a complete list of antibodies and fluorochromes used 
in the study, see Table S1 in Supplementary Material.
iFnγ elisPOT
Draining lymph nodes from immunized mice were harvested 
3 days post-boost (DOL 17). Nitrocellulose 96-microwell plates 
(Millipore) were coated with 75  µl/well of anti-mouse IFNγ  
(10 µg/ml in PBS, clone R4-6A2, BD Pharmingen) overnight at 4°C, 
washed twice with wash buffer (PBS + Tween-20 0.05%) and once 
with distilled water. Wells were blocked with 200 µl of complete 
culture medium for 2  h at RT. Single-cell suspensions of dLNs 
in complete culture medium supplemented with recombinant 
mouse IL-2 (5 ng/ml, PeproTech) were added to the wells in the 
presence or absence of 10 µg/ml of Flublok and 2 µg/ml anti-mouse 
CD28 (Biolegend) and cultured for 18 h. Wells were then washed 
and incubated with 100 ml of biotinylated anti-mouse IFNγ (5 µg/
ml in PBS + FBS 10%, clone XMG1.2, BD Pharmingen) for 2 h at 
RT, washed again and incubated with 100μl of streptavidin-alka-
line phosphatase (1:1000 dilution in PBS + FBS 10%, MabTech) 
for 1  h prior to color development using BCIP/NBT substrate 
(Biorad) as per manufacturer’s protocol. Spots on air-dried plates 
were counted on an ImmunoSpot Analyzer.
statistical analyses and graphics
Data were analyzed and graphed using Prism for MacIntosh 
v. 7.0 (GraphPad Software). Tests used for statistical comparisons 
are indicated in figure legends. p-value <0.05 was considered 
significant.
resUlTs
Phenotypic and Functional 
characterization of neonatal BMDcs
Murine BMDCs represent a widely used model to study DC 
function in  vitro. Adult BMDCs represent a heterogeneous 
population composed of CD11c+ macrophage-like and DC-like 
cells with distinct phenotypic and functional profiles (54). 
However, murine neonatal BMDCs have never been character-
ized in depth. Therefore, we first sought to define the phenotypic 
and functional properties of neonatal BMDCs. Although the 
cell yield from neonatal bone marrow was lower compared to 
adult ones (Figures S1A,B in Supplementary Material), neonatal 
immature BMDCs generated from 7-day-old mice grew in 
culture similarly to adult cells (Figure S1C in Supplementary 
Material), and once fully differentiated they expressed similar 
levels of CD11c compared to adult cells but significantly lower 
levels of MHCII (Figures S1D,E in Supplementary Material). 
To further characterize phenotypic differences between 
newborn and adult BMDCs, we assessed by flow cytometry 
the expression of different macrophage and DC markers. As 
previously reported for adult BMDCs (54), neonatal BMDCs 
also comprised CD11c+ MHCII-low and CD11c+ MHCII-high 
cells. Of note, the percentage of MHCII-low cells was higher 
in neonatal BMDCs compared to adult BMDCs. Neonatal 
MHCII-low BMDCs also expressed higher levels macrophage-
associated markers (CD64, CD115, CD11b, F4/80) compared to 
MHCII-high BMDCs, while this population expressed higher 
levels of CD117. No significant differences in surface marker 
expression were found between corresponding neonatal and 
adult MHCII-high and -low populations, except for neonatal 
MHCII-low BMDCs that expressed higher levels of F4/80 and 
neonatal MHCII-high BMDCs that expressed higher levels of 
CD117 compared to their adult counterparts (Figures S2A,B in 
Supplementary Material).
To characterize a functional response of newborn BMDCs, 
we next assessed cytokine production and upregulation of co-
stimulatory molecules in response to the TLR4 agonist smooth 
LPS. While newborn BMDC production of IL-6 and TNF was, 
respectively, comparable or slightly lower than adult BMDCs, 
IL-12p70 production, albeit detectable, was markedly reduced 
compared to adult BMDCs (Figure S3A in Supplementary 
Material). The latter result might be consistent with a more 
macrophage-like phenotype of newborn BMDCs. As previ-
ously reported, both adult and newborn BMDCs produced 
IL-1β in response to rough but not smooth LPS (55), with 
newborn BMDCs producing slightly higher amounts of IL-1β 
(Figure S3B in Supplementary Material). Finally, newborn 
BMDCs expressed lower levels of MHCII, CD40, and CD86 
in response to smooth LPS (Figures S3C,D in Supplementary 
Material).
identification of sTing as a Target for 
inducing neonatal BMDc Maturation
Having characterized phenotypic and functional features of 
neonatal and adult BMDCs, we next assessed their response to a 
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panel of PRR agonists and adjuvants (Table S2 in Supplementary 
Material). As readouts we measured cytokine production (TNF, 
IL-1β, IL-6, and IL-12p70) and surface expression of matura-
tion markers (CD40, CD80, and CD86). At the most effective, 
non-toxic (as established in preliminary experiments, data not 
shown) concentration of each agonist (in bold in Table S2), 
neonatal BMDCs produced similar amounts of TNF, IL-6, and 
IL-1β compared to adult BMDCs in response to different TLR7/8 
agonists, namely R848 (Resiquimod, imidazoquinoline), CL075 
(thiazoloquinolone) or CL264 (9-benzyl-8 hydroxyadenine), 
but again failed to produce IL-12p70 (Figure 1A). Remarkably, 
the upregulation of surface maturation marker expression on 
neonatal BMDCs was much lower than adult BMDCs upon any 
PRR stimulation, with the exception of the STING agonist 2′3′-
cGAMP (hereafter cGAMP) (Figure 1B). To assess in depth the 
response to STING and TLR7/8 agonists, we stimulated neonatal 
and adult BMDCs with different concentrations of cGAMP 
and R848. We confirmed that R848 induced higher produc-
tion of TNF and IL-12p70 (the latter only in adult BMDCs), 
while cGAMP was more effective than R848 at upregulating 
the expression of surface maturation markers (Figure  1C). 
cGAMP also induced dose-dependent IFNβ production in both 
newborn and adult BMDCs (Figure 1C). Of note, the response of 
neonatal and adult BMDCs to cGAMP was comparable (Figure 
S4 in Supplementary Material). Using neutralizing antibodies 
against TNF or type I IFN receptor (IFNAR), we demonstrated 
that the expression of maturation markers by neonatal BMDCs 
mostly relies on type I IFN signaling (Figure S5 in Supplementary 
Material).
cgaMP Formulated with alum enhances 
anti-rha igg2a/c antibody Titers in an 
early life immunization Model
The in vitro results obtained so far supported further investiga-
tion of cGAMP as adjuvant candidate for early life immuniza-
tion. Therefore, we proceeded to test this hypothesis in vivo. We 
immunized newborn (7-day old) and adult (8- to 10-week old) 
C57BL/6 mice using a prime-boost schedule (Figure 2A) and 
employing trivalent recombinant hemagglutinin (rHA) influ-
enza vaccine Flublok as clinically relevant model antigen that is 
devoid of adjuvant, alone, or formulated with alum [Alhydrogel, 
Al(OH)3], cGAMP or (cGAMP  +  alum) (Figure  2B). Mice 
were bled 14, 21, 28, and 35 days post-prime (respectively, day 
of life (DOL) 21, 28, 35, and 42 for newborn mice) to assess the 
magnitude and kinetic of the antibody response. As expected, 
both alum and cGAMP increased anti-rHA IgG titers in adult 
mice. We also investigated the titers of the IgG subclasses 
IgG1 and IgG2c, respectively associated with type 2 and type 
1 (IFNγ-driven) immunity (56, 57). In keeping with previously 
published data, alum preferentially increased anti-rHA IgG1 
titers (median anti-rHA IgG1 titers at Day 35 post-prime: 
5.02 × 106 for alum, 0.77 × 106 for cGAMP), while cGAMP was 
more effective than alum at enhancing anti-rHA IgG2c titers 
(median anti-rHA IgG2c titers at day 35 post-prime: 0.16 × 106 
for alum, 0.82 × 106 for cGAMP). (cGAMP + alum) was as effec-
tive as alum at increasing anti-rHA IgG and IgG1 titers [median 
anti-rHA IgG and IgG1 titers at day 35 post-prime: respectively, 
4.77 × 106 and 4.46 × 106 for (cGAMP + alum)], and even more 
effective than cGAMP alone at enhancing anti-rHA IgG2c titers 
[median anti-rHA IgG2c titers at day 35 post-prime: 3.27 × 106 
for (cGAMP + alum)] (Figure 2B, upper panels and Figure S6 
in Supplementary Material). In newborn mice, we unexpectedly 
found that cGAMP was much less effective at increasing anti-
rHA IgG, IgG1, and IgG2c titers [median anti-rHA IgG, IgG1, 
and IgG2c titers at day 35 post-prime (DOL 42): respectively, 
20.57 ×  103, 24.51 ×  103, and 0.23 ×  103 for cGAMP]. Alum 
enhanced anti-rHA IgG and IgG1 titers, but in marked contrast 
from adult mice it did not induce anti-rHA IgG2c titers [median 
anti-rHA IgG, IgG1, and IgG2c titers at day 35 post-prime 
(DOL 42): respectively, 48.35 × 103, 143.23 × 103, and 0.00 × 103 
for alum]. Surprisingly, (cGAMP  +  alum) adjuvantation 
matched or exceeded alum at increasing anti-rHA IgG and IgG1 
titers [median anti-rHA IgG and IgG1 titers at Day 35 post-
prime (DOL 42): respectively, 329.19 ×  103 and 167.83 ×  103 
for (cGAMP + alum)], and, remarkably, also induced relatively 
high titers of anti-rHA IgG2c as early as 14  days post-prime 
(DOL 21) [median anti-rHA IgG2c titers at day 14 (DOL 21) 
and day 35 post-prime (DOL 42): respectively, 0.14 × 103 and 
4.23 × 103 for (cGAMP + alum)] (Figure 2B, lower panels and 
Figure S7 in Supplementary Material). Therefore, the addition 
of cGAMP to alum markedly enhanced anti-rHA antibody 
production (in particular IgG2c), with a more prominent effect 
in newborn than adult mice (~400 as compared to ~150-fold 
increase, respectively) (Figure 2C). Interestingly, newborn mice 
immunized at DOL 7 and 14 (as indicated in Figure 2B) with 
(cGAMP +  alum) still display the highest anti-rHA IgG and 
IgG2c titers at DOL 90 compared to saline and alum groups 
(Figure S8 in Supplementary Material). Enhancement of anti-
rHA IgG and IgG2a titers induced by (cGAMP + alum) was also 
demonstrable in the Th2-skewed mouse strain BALB/c (Figure 
S9 in Supplementary Material).
In light of the robust adjuvanticity of the (cGAMP + alum) 
formulation, we quantified cGAMP adsorption to alum by 
RP-HPLC (Table 1). We observed a rapid initial adsorption of 
cGAMP onto alum (63% of total cGAMP) within 15 min from 
the incubation. The adsorption rate dropped quickly, with the 
overall adsorption reaching a plateau (75.33% of total cGAMP) 
after 24  h of incubation. No significant degradation products 
were observed over this time window.
Altogether, our in vivo results demonstrate that (cGAMP + alum) 
is an effective formulation to enhance antigen-specific antibody 
titers (especially of the IgG2a/c subclass) for early life immunization.
(cgaMP + alum) Fosters Th1 Polarization 
and gc reaction
IgG2a/c isotype switching is driven by IFNγ in  vivo (58), and 
reduced in early life, since newborns display reduced IFNγ pro-
duction and Th1 polarization to many stimuli (6, 7). Therefore, 
we investigated whether (cGAMP + alum) was able to modulate 
the polarization and cytokine production of antigen-specific 
T  cells. Accordingly, newborn mice were immunized as indi-
cated in Figure  2A with alum or (cGAMP +  alum). Ten days 
FigUre 1 | Screening of pattern recognition receptor (PRR) agonists on neonatal and adult BMDCs. (a–c) Newborn (N) and adult (Ad) BMDCs were stimulated 
with the indicated PRR agonists or adjuvants for 20–24 h. Cytokine production (a,c) and MFI of surface marker expression (B,c) were, respectively, assessed by 
ELISA and flow cytometry. (a,B) Color intensities of the heatmaps are proportional to (a) mean cytokine levels (expressed as pg/ml) or (B) mean co-stimulatory 
molecule levels (expressed as fold change of median fluorescence intensity over CTRL) of 5–6 (a) or 3 (B) independent experiment. (c) Results are expressed as 
mean + SEM of 4–5 (cytokine production) or 3 (surface marker expression) independent experiments. *p < 0.05, **p < 0.01 determined by repeated measures 
two-way ANOVA with Sidak post hoc test.
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post-boost, splenocytes were harvested, re-stimulated with 
rHA in the presence or absence of the co-stimulus αCD28, and 
cytokine production by CD4+ T  cells was measured by flow 
cytometry (Figure  3A). While IL-2- and IL-4-producing cells 
were observed in both groups, IFNγ+ CD4+ T (Th1) cells were 
only detected among splenocytes isolated from mice immunized 
TaBle 1 | cGAMP adsorption onto alum as function of time as assessed by 
RP-HPLC.
cgaMP adsorbed onto alum—incubated at 37°c
Time point Peak area (maU) % adsorbed to alum
15 min 22.53 63.00
30 min 22.93 62.34
1 h 22.22 63.51
2 h 20.83 65.79
4 h 21.02 65.48
24 h 15.02 75.33
Alum control (no cGAMP) 0.53 ND
Saline 0.55 ND
RP-HPLC, reverse-phase high performance liquid chromatography.
FigUre 2 | Immunization with recombinant hemagglutinin (rHA) formulated with cGAMP and alum induces distinct antibody profiles in adult and newborn mice. (a) 
Schematic representation of the immunization schedule for adult (day post-priming is indicated) and newborn [day of life (DOL) is indicated] mice. (B) Adult (top) and 
newborn (bottom) mice were immunized i.m. with saline (black line), rHA (brown line), (rHA + alum) (blue line), (rHA + cGAMP) (orange line) or (rHA + cGAMP + alum) 
(red line), and antibody titers for rHA-specific IgG, IgG1, and IgG2c were determined by ELISA in serum samples collected at the reported timepoints. (c) Fold 
change of median Ab titers over (rHA + alum) group. White bars, newborn mice. Black bars, adult mice. Results are shown as median of 9–10 (adult) or 7–8 
(newborn) mice per group. *, +, #p < 0.05, **, ++, ##p < 0.01 of groups indicated by the corresponding color, respectively, vs. saline, rHA, and (rHA + alum) groups 
determined by Kruskal–Wallis with Dunn’s post hoc test.
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with (cGAMP  +  alum) [median percentages of IFNγ+ CD4+ 
T cells upon rHA re-stimulation: 0.000 for saline, 0.031 for alum, 
and 0.295 for (cGAMP +  alum) groups; upon rHA + αCD28 
re-stimulation: 0.009 for saline, 0.021 for alum, and 0.280 for 
(cGAMP +  alum) groups]. No IL-17 production was observed 
in any of the tested conditions (Figure 3B). To corroborate this 
evidence, upon in  vitro re-stimulation with rHA + αCD28 we 
found by ELISPOT a higher number of IFNγ-producing cells 
in the dLNs of mice immunized with (cGAMP + alum) 3 days 
post-boost (Figure 4).
T  cell-dependent antibody generation is initiated in GCs 
and guided by Tfh cells (59, 60). Since GCs are major sites for 
isotype switching, we reasoned that immunization of newborn 
mice with (cGAMP + alum) might promote the GC reaction, 
thereby inducing IgG2a/c switching. To this aim, we assessed 
by flow cytometry the percentages and absolute numbers of GC 
Tfh and B cells (respectively, identified as viable singlet CD45+ 
B220− CD3+ CD4+ CXCR5+ PD-1+ and CD45+ CD3− B220+ 
GL-7+ CD138− cells) in dLNs 10 days post-boost of newborn 
mice immunized with alum or (cGAMP + alum). Interestingly, 
we found a significant increase in the percentage [median: 0.275 
for saline, 0.42 for alum, and 0.925 for (cGAMP + alum)] and 
absolute number [median: 1,360 for saline, 2,558 for alum, 
and 5,754 for (cGAMP + alum)] of GC Tfh cells and the per-
centage [median: 14.4 for saline, 19.7 for alum, and 27.35 for 
(cGAMP +  alum)] and absolute number [median: 10,975 for 
saline, 19,878 for alum, and 42,524 for (cGAMP +  alum)] of 
GC B  cells only in the (cGAMP +  alum) group (Figure  5A). 
Immunization with alum induced a small increase in the per-
centage (but not absolute number) of GC B  cells, while only 
minor modifications of the percentages and absolute numbers 
of total CD4+ T cells and B cells were observed across different 
immunization groups (Figures 5A,B).
The GC is also the site where the processes of somatic 
hypermutation of antibody variable region genes and generation 
of high-affinity antibodies take place (60). To verify whether 
cGAMP modulates antibody affinity maturation, we measured 
rHA-specific IgG avidity of newborn mice immunized with alum 
or (cGAMP +  alum) as indicated in Figure  2A. Although we 
observed a steep increase in antibody avidity 21 days post prime 
(DOL 28) which reached a plateau later on [28 (DOL 35) and 
35 (DOL 42) days post-prime], no differences between the two 
groups were detected at any time point (Figure 6).
Overall, these results demonstrate that the addition of cGAMP 
to alum promoted the induction of IFNγ-producing T cells and 
appeared to foster the GC reaction, which might in turn drive 
IgG2a/c isotype switching in our early life immunization model.
single-Dose immunization with 
(cgaMP + alum) induces rha-specific 
igg2c antibodies
The results obtained so far supported the efficacy of 
(cGAMP + alum) as an adjuvantation system in a prime/boost 
model of neonatal murine immunization. Of note, a single-dose 
immunization strategy capable of enhancing antigen-specific 
antibody titers would be highly desirable early in life. To this 
end, we immunized newborn mice with rHA formulated with 
alum, cGAMP, or (cGAMP +  alum). Distinct from its effects 
in prime/boost immunization, cGAMP without alum did not 
induce detectable anti-rHA IgG, IgG1, and IgG2c titers. Alum 
and (cGAMP + alum) significantly increased anti-rHA IgG and 
IgG1 titers [median anti-rHA IgG and IgG1 titers: respectively, 
26.74 ×  103 and 52.08 ×  103 for alum; respectively, 1.07 ×  106 
and 1.48  ×  106 for (cGAMP  +  alum)]. Interestingly, only 
(cGAMP +  alum) induced detectable levels of anti-rHA IgG2c 
(median: 571.9), albeit at lower levels compared to prime/boost 
immunization (Figure 7). Altogether, these results demonstrate 
that (cGAMP + alum) is an effective adjuvantation system also 
for single dose early life immunization.
DiscUssiOn
Over the past decades, many PRRs and their agonists have been 
identified, and the molecular definition of their mechanisms of 
action and immunostimulatory properties has paved the way for 
new classes of adjuvants (26, 61). For example, the TLR4 agonist 
monophosphoryl lipid A is employed in different FDA-approved 
vaccine formulations. Despite this wealth of knowledge, the 
portfolio of adjuvants approved or in clinical development for 
FigUre 3 | Immunization with (cGAMP + alum) induces Th1 polarization in early life. Newborn mice were immunized with alum or (cGAMP + alum) as indicated in 
Figure 2a. Ten days after boost [day of life (DOL) 24] splenocytes were harvested, re-stimulated for 18 h with recombinant hemagglutinin (rHA) in the presence or 
absence of the co-stimulus αCD28, and cytokine production by CD4+ T cells was assessed by intracellular flow cytometry. (a) Representative gating strategy. CD4+ 
T cells were defined as viable singlet CD3+ CD4+ cells. (B) Results are shown as the median, the 25th and 75th percentiles (boxes) and the 5th and 95th percentiles 
(whiskers) of 9–10 mice per group. **p < 0.01 of in vitro CTRL vs. rHA vs. rHA + αCD28, ++p < 0.01 of respective in vitro conditions compared to in vivo saline 
group, #p < 0.05 and ##p < 0.01 of respective in vitro conditions compared to in vivo alum group, determined by two-way ANOVA with Tukey’s post hoc test.
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the newborn and the young infant is much narrower, in part due 
to our limited knowledge of the immune system early in life (6, 7, 
62). Notwithstanding these limitations, in vitro and pre-clinical 
in vivo studies have shown that targeting some PRRs, in particular 
TLR7/8 (8–14), potently activates newborn immune cells and 
markedly enhances vaccine efficacy early in life. Here, by combin-
ing an in vitro analysis of newborn BMDC activation in response 
to PRR agonists and in vivo immunization models, we identify 
the STING agonist cGAMP as adjuvant candidate for early life 
immunization. In particular, we demonstrate that immunization 
of newborn mice with cGAMP formulated with alum appears to 
foster the GC reaction as well as features of IFNγ-driven type 1 
immunity, namely switching toward IgG2a/c subclass and Th1 
polarization.
Although there is no comprehensive consensus on whether 
and how in vitro models can predict the in vivo effect of candidate 
adjuvants, the use of DCs has some advantages for assessing their 
activity in vitro (6, 27, 63, 64). First, DCs are the most prominent 
subset of antigen-presenting cells. Second, they express many 
PRRs. Third, DCs can be employed to recapitulate age-specific 
differences. Although isolating primary DCs from spleen and 
lymph nodes of neonatal mice would be ideal, this approach 
is cumbersome if not impossible due to low cell yield (65, 66). 
Therefore, we developed and characterized a neonatal BMDC 
FigUre 4 | Immunization with (cGAMP + alum) induces IFNγ-producing 
cells in draining lymph nodes (dLNs) of newborn mice. Newborn mice were 
immunized with alum or (cGAMP + alum) as indicated in Figure 2a. 3 days 
after boost [day of life (DOL) 17] cells were isolated from dLNs, re-stimulated 
for 18 h with rHA + αCD28, and the number of IFNγ-producing cells per LN 
was assessed by ELISPOT. Results are shown as the median, the 25th and 
75th percentiles (boxes) and the fifth and 95th percentiles (whiskers) of 4–5 
mice per group. **p < 0.01 of in vitro CTRL vs. rHA + αCD28, ++p < 0.01 of 
respective in vitro conditions compared to in vivo saline group, ##p < 0.01 of 
respective in vitro conditions compared to in vivo alum group, determined by 
two-way ANOVA with Sidak’s post hoc test.
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model, and found phenotypic and functional differences between 
neonatal and adult BMDCs. Most importantly, by comparing the 
activation profiles of neonatal and adult BMDCs we identify 
that the STING agonist cGAMP induces their maturation (e.g., 
upregulation of CD40, CD80, and CD86). Although we proceeded 
in assessing the in vivo adjuvant activity of cGAMP, we cannot 
exclude that other PRR ligands that did not activate newborn 
BMDCs in vitro might act as adjuvants in vivo. Therefore, further 
studies, especially of combination formulations, are required to 
define the predictive value of the in vitro newborn BMDC system.
Cyclic dinucleotides including cGAMP have been tested as 
candidate adjuvants in experimental models of parenteral or 
mucosal adult immunization (32–49). In the present work, mice 
were immunized by the intramuscular route as it is commonly 
employed for pediatric vaccines: a new formulation specific for 
intramuscular injection may fit easily with other vaccines in the 
pediatric vaccination schedule, while intranasal immunization 
against influenza virus, for example, is currently not recom-
mended by the CDC (67). We found that free cGAMP, simply 
injected together with the model antigen, is much less effective in 
newborn than in adult mice at increasing antigen-specific anti-
body titers. Remarkably, cGAMP formulated with alum induces 
relatively high titers of antigen-specific IgG2a/c compared to 
alum or cGAMP alone, especially in newborn mice immunized 
with prime/boost or single dose schedules. The explanation for 
this might be that about 60% of cGAMP adsorbs onto alum 
in vitro, which also suggests that there is still the possibility of 
further optimizing this formulation and increasing the percent-
age of adsorbed cGAMP by modification of the adsorption pH, 
buffer, and alum to cGAMP ratio. Interestingly, it has already been 
reported that CDNs tend to diffuse in the bloodstream after injec-
tion, while their nanoparticle formulations deliver CDNs to the 
dLNs (40). It is tempting to speculate that the same phenomenon 
might explain the differences in the efficacy between cGAMP and 
(cGAMP + alum). In addition, it will be interesting to compare 
the effect of optimized (cGAMP + alum) and nanoparticle-based 
cGAMP formulations in our early life immunization model.
Newborns and young infants have a distinct immunity with 
an impairment of IFNγ-driven type 1 immunity, which in turn 
leads to reduced vaccine efficacy and higher risk of infections 
(6, 7). By using (cGAMP + alum) as adjuvantation strategy for 
early life immunization, we were able to induce cardinal features 
of type 1 immunity: (1) IFNγ production by antigen-specific 
CD4+ T  cells and (2) relatively high titers of antigen-specific 
IgG2a/c. As IFNγ promotes isotype switching toward IgG2a/c 
in vivo (58), these two events are likely linked. The importance 
of inducing this antibody subclass relies in its higher affinity 
toward Fcγ receptors expressed on myeloid cells, which endows 
this subclass with greater effector functions (e.g., induction of 
phagocytosis, complement fixation) that may be important for 
protecting from infections (56, 57). Our results also suggest that 
(cGAMP + alum) increases the magnitude of the GC reaction, 
known to be impaired in early life (24, 25), by inducing higher 
percentages and absolute numbers of GC Tfh and B cells in dLNs. 
Although we cannot exclude that the GC reaction induced by 
alum follows a different kinetics, these results might represent 
the cellular correlate of the isotype switching and early IgG2a/c 
production observed in the (cGAMP + alum) group. Altogether, 
our data point to a relevant effect of the (cGAMP + alum) for-
mulation on the humoral and cellular immune responses elicited 
upon immunization early in life.
Overall, our study features several strengths, including (a) the 
first immunophenotypic characterization of murine neonatal 
BMDCs, (b) an unbiased screening of PRR agonists for activity 
toward neonatal BMDCs, and (c) identification of a novel adju-
vantation system active in vitro and in vivo with evidence sup-
porting potential utility in enabling single-dose immunization at 
birth. Our study also has limitations, including (a) the neonatal 
BMDC model studied represents a mix of cells generated by treat-
ment with cytokines in vitro such that they may not fully reflect 
in  vivo biology, (b) the potential effects of (cGAMP +  alum) 
on GCs are intriguing but until such time as they are verified 
by microscopy are inferential, (c) although our studies demon-
strated robust increases in antibody titers and features of type 
1 immunity elicited by immunization with (cGAMP +  alum), 
future functional studies (e.g., pathogen challenge) are required 
to assess the efficacy of this adjuvantation system, and (d) due to 
species specificity, results in mice may not accurately reflect those 
in humans.
In conclusion, we demonstrate that cGAMP is a promising 
and robust adjuvant candidate for early life immunization. We 
also show that cGAMP formulated with alum potently enhances 
humoral and cellular aspects of type 1 immunity in early life. Since 
we employed the rHA influenza vaccine throughout our work, 
FigUre 5 | Immunization with (cGAMP + alum) fosters the germinal center (GC) reaction. Newborn mice were immunized with alum or (cGAMP + alum) as indicated 
in Figure 2a. Ten days after boost [day of life (DOL) 24] cells were isolated from draining lymph nodes and the percentages and absolute numbers of CD4+ T cells, 
B cells, GC Tfh, and B cells were assessed by flow cytometry. [(a,B) top panels] Representative gating strategies. CD4+ T cells were defined as viable singlet CD45+ 
B220− CD3+ CD4+ cells. GC Tfh cells were defined as viable singlet CD45+ B220− CD3+ CD4+ CXCR5+ PD-1+ cells. B cells were defined as viable singlet CD45+ B220+ 
CD3− cells. GC B cells were defined as viable singlet CD45+ B220+ CD3− GL-7+ CD138− cells. (B) Results are shown as the median, the 25th and 75th percentiles 
(boxes) and the 5th and 95th percentiles (whiskers) of 9–10 mice per group. *p < 0.05, **p < 0.01 determined by one-way ANOVA with Holm–Sidak’s post hoc test.
FigUre 6 | Continued
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FigUre 7 | Single-dose immunization of newborn mice with (cGAMP + alum) significantly increases anti-recombinant hemagglutinin (rHA) IgG2c titers. Newborn 
mice were immunized i.m. with saline, rHA alone or formulated with alum, cGAMP or (cGAMP + alum) and antibody titers for rHA-specific IgG, IgG1, and IgG2c 
were determined by ELISA in serum samples collected 28 days after boost [day of life (DOL) 35]. Results are shown as the median, the 25th and 75th percentiles 
(boxes), and the 5th and 95th percentiles (whiskers) of 9–13 mice per group. **p < 0.01 determined by Kruskal–Wallis with Dunn’s post hoc test.
FigUre 6 | Immunization with (cGAMP + alum) does not modulate recombinant hemagglutinin (rHA)-specific IgG avidity. Newborn mice were immunized with rHA 
formulated with alum or (cGAMP + alum) and serum samples were collected as indicated in Figure 2. Avidity of rHA-specific IgG was measured by ELISA and 
expressed as the ratio between the LogEC50 values obtained with and without ammonium thiocyanate treatment (0.5 M). Results are shown as median (left panel) 
or as the median, the 25th and 75th percentiles (boxes) and the 5th and 95th percentiles (whiskers) (right panels) of 7–8 newborn mice per group. *p < 0.05, 
**p < 0.01 determined by two-way ANOVA with Sidak’s post hoc test (left panel) or Mann-Whitney test (right panels).
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our results may be applicable to influenza immunization. Use of 
(cGAMP + alum) may also represent a general strategy to elicit type 
1 immunity toward protein antigens for early life immunization.
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